Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3195-3201

  Verma, Rahul Kumar ^a   Kaur, Jatinder ^a   Kumar, Kaushlendra ^a   Yadav, Awadh Bihari ^a   Misra, Amit ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PHORBOL; RIFABUTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARATUS; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CELL CULTURE; CELL LEVEL; CONCENTRATION (PARAMETERS); DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; LUNG; LUNG ALVEOLUS MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SAMPLE; TIME;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; FEMALE; ISONIAZID; KIDNEY; LIVER; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; RIFABUTIN; TIME FACTORS;

EID: 50949086685     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00153-08     Document Type: Article

References (40)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Barger, A., C. Fuhst, and B. Wiedemann. 2003. Pharmacological indices in antibiotic therapy. J. Antimicrob. Chemother. 52:893-898.
3. Blaschke, T. F., and M. H. Skinner. 1996. The clinical pharmacokinetics of rifabutin. Clin. Infect. Dis. 22(Suppl. 1):S15-S21.
4. Brogden, R. N., and A. Fitton. 1994. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:983-1009.
5. Burman, W., D. Benator, A. Vernon, A. Khan, B. Jones, C. Silva, C. Lahart, S. Weis, B. King, B. Mangura, M. Weiner, and W. El-Sadr. 2006. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173:350-356.
6. Calleja, I., M. J. Blanco-Príeto, N. Ruz, M. J. Renedo, and M. C. Dios-Viéitez. 2004. High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. 1031:289-294.
7. Cox, H. S., M. Morrow, and P. W. Deutschmann. 2008. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336:484-487.
8. Delahunty, T., B. Lee, and J. E. Conte. 1998. Sensitive liquid chromatographic technique to measure isoniazid in alveolar cells, bronchoalveolar lavage and plasma in HIV-infected patients. J. Chromatogr. B 705:323-329.
9. Donald, P. R. 2006. The early bactericidal activity of anti-tuberculosis agents. Int. J. Tuberc. Lung Dis. 10:591.
10. Gumbo, T., A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
11. Gumbo, T., A. Louie, W. Liu, P. G. Ambrose, S. M. Bhavnani, D. Brown, and G. L. Drusano. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201.
12. Gumbo, T., A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51:2329-2336.
13. Hestvik, A. L., Z. Hmama, and Y. Av-Gay. 2005. Mycobacterial manipulation of the host cell. FEMS Microbiol. Rev. 29:1041-1050.
14. Hirata, T., H. Saito, H. Tomioka, K. Sato, J. Jidoi, K. Hosoe, and T. Hidaka. 1995. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:2295-2303.
15. Holdiness, M. R. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544.
16. Hutchings, A., R. D. Monie, B. Spragg, and P. A. Routledge. 1983. High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J. Chromatogr. 277:385-390.
17. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
18. Kaur, J., P. Muttil, R. K. Verma, K. Kumar, A. B. Yadav, R. Sharma, and A. Misra. 2008. A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur. J. Pharm. Sci. 34:56-65.
19. Makino, K., T. Nakajima, M. Shikamura, F. Ito, S. Ando, C. Kochi, H. Inagawa, G. Soma, and H. Terada. 2004. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. B 36:35-42.
20. Reference deleted.
21. Muttil, P., J. Kaur, K. Kumar, A. B. Yadav, R. Sharma, and A. Misra. 2007. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32:140-150.
22. O'Hara, P., and A. J. Hickey. 2000. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 17:955-961.
23. Pandey, R., and G. K. Khuller. 2005. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinburgh) 85:227-234.
24. Pandey, R., A. Sharma, A. Zahoor, S. Sharma, G. K. Khuller, and B. Prasad. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52:981-986.
25. Pandey, R., S. Sharma, and G. K. Khuller. 2004. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. Indian J. Exp. Biol. 42:562-566.
26. Pandey, R., S. Sharma, and G. K. Khuller. 2004. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int. J. Antimicrob. Agents 24:93-94.
27. Russell, D. G. 2007. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5:39-47.
28. Schaaf, H. S., D. P. Parkin, H. I. Seifart, C. J. Werely, P. B. Hesseling, P. D. van Helden, J. S. Maritz, and P. R. Donald. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90:614-618.
29. Sharma, R., P. Muttil, A. B. Yadav, S. K. Rath, V. K. Bajpai, U. Mani, and A. Misra. 2007. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59:499-506.
30. Sharma, R., D. Saxena, A. K. Dwivedi, and A. Misra. 2001. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18:1405-1410.
31. Skinner, M. H., and T. F. Blaschke. 1995. Clinical pharmacokinetics of rifabutin. Clin. Pharmacokinet. 28:115-125.
32. Skinner, M. H., M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen, T. C. Merigan, and T. F. Blaschke. 1989. Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother. 33:1237-1241.
33. Suarez, S., P. O'Hara, M. Kazantseva, C. E. Newcomer, R. Hopfer, D. N. McMurray, and A. J. Hickey. 2001. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48:431-434.
34. Suarez, S., P. O'Hara, M. Kazantseva, C. E. Newcomer, R. Hopfer, D. N. McMurray, and A. J. Hickey. 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18:1315-1319.
35. Tannen, R. H., and W. W. Weber. 1979. Rodent models of the human isoniazid-acetylator polymorphism. Drug Metab. Dispos. 7:274-279.
36. Weber, W. W., and D. W. Hein. 1979. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 4:401-422.
37. Weiner, M., D. Benator, W. Burman, C. A. Peloquin, A. Khan, A. Vernon, B. Jones, C. Silva-Trigo, Z. Zhao, and T. Hodge. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40: 1481-1491.
38. Yadav, A. B., and A. Misra. 2007. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity. Antimicrob. Agents Chemother. 51:3740-3742.
39. Yoshida, A., M. Matumoto, H. Hshizume, Y. Oba, T. Tomishige, H. Inagawa, C. Kohchi, M. Hino, F. Ito, K. Tomoda, T. Nakajima, K. Makino, H. Terada, H. Hori, and G. Soma. 2006. Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin. Microbes Infect. 8:2484-2491.
40. Zahoor, A., S. Sharma, and G. K. Khuller. 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26:298-303.